Dihydroorotate dehydrogenase Inhibitors
2 drugsAbout Dihydroorotate dehydrogenase
Dihydroorotate dehydrogenase (DHODH) is an enzyme essential for de novo pyrimidine synthesis, providing crucial building blocks for DNA and RNA. It catalyzes the fourth step in pyrimidine biosynthesis, making it vital for cell proliferation and function.
DHODH is a clinically validated drug target, evidenced by two FDA-approved drugs. While there is currently no genetic evidence directly linking DHODH to specific diseases, its inhibition offers therapeutic benefit in autoimmune conditions.
Two FDA-approved small molecule drugs, TERIFLUNOMIDE (AUBAGIO) and TERIFLUNOMIDE, target DHODH. These drugs, developed by MSN and Sanofi, are used in CNS and other therapeutic areas, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in HAM/TSP with only 1 trials.
- phase2 represents biological uncertainty with 33% completion.
Top Dihydroorotate dehydrogenase Drugs
The competitive landscape includes two companies, MSN and Sanofi, with approved DHODH-targeting drugs.
Limited competition suggests opportunity, but high barriers to entry due to established players.
Dihydroorotate dehydrogenase Drug Modality Landscape
Modalities
Routes of Administration
Dihydroorotate dehydrogenase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like PROTACs or biologics to differentiate from existing therapies.
Dihydroorotate dehydrogenase Clinical Trials 39 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 3 | 1 | 1 | 75% |
| Phase 2 | 4 | 2 | 1 | 1 | 67% |
| Phase 3 | 25 | 15 | 3 | 7 | 83% |
| Phase 4 | 5 | 5 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved Dihydroorotate dehydrogenase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Dihydroorotate dehydrogenase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Dihydroorotate dehydrogenase Drug Approval Timeline (2012 - 2018)
The first DHODH-targeting drug was approved in 2012, with the most recent approval in 2018.
The relatively short approval span indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 39 clinical trials targeting Dihydroorotate dehydrogenase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities